Make Your First AppointmentGet a Second Opinion
Call us: 877-442-3324
The Breast Oncology Program at the Susan F. Smith Center for Women's Cancers at Dana-Farber provides state-of-the-art and compassionate care for breast cancer patients. Our breast cancer clinicians are committed to providing you with the best and most individualized treatment options available, taking advantage of the full range of services of a top-ranked cancer hospital and research center. Ending women's cancers including breast cancer is the reason we exist – everything we do is tailored to the unique needs of women.
Our focused services include expertise in metastatic breast cancer, as well as programs for young women with breast cancer, inflammatory breast cancer, male breast cancer, breast cancer during pregnancy, and breast and ovarian cancer genetics and prevention.
Michelle MaloneyCancer survivor
We want to keep you fully informed about all that's happening at the Susan F. Smith Center at Dana-Farber. Read about our latest progress in breast cancer research, see media coverage of our breast cancer researchers and clinicians, read blog posts on a variety of topics pertaining to breast cancer.
July 20, 2014Dr. Harold Burstein commented on contraleteral prophylactic mastectomies.
July 10, 2014Dr. Eric Winer co-chaired an expert panel that developed a clinical practice guideline on disease management for patients with advanced HER2-positive breast cancer and brain metastases.
July 10, 2014Dr. Ian Crop led a study showing that the antibody-drug conjugate ado-trastuzumab emtansine significantly prolonged progression-free survival in patients with progressive HER2-positive advanced breast cancer.
June 20, 2014Dr. Erica Mayer, a medical oncologist at the Susan F. Smith Center for Women's Cancers at Dana-Farber, explains the concerns over soy consumption and its relationship to breast cancer.
June 9, 2014Dr. J. Dirk Iglehart comments that he now performs about a tenth of the number of mastectomies as when he entered the field in the 1970s.
May 31, 2014Dr. Ann Partridge provides insight into the study of a drug that can protect ovaries from damage caused by chemotherapy.
May 29, 2014A pilot phase 2 clinical trial led by researchers at Dana-Farber Cancer Institute is testing the feasibility of the targeted drug palbociclib combined with endocrine therapy as adjuvant therapy for stage II and III breast cancer.
May 29, 2014Results from an open label clinical study, evaluating an oral daily dose of the drug enobosarm, shows promise for women with metastatic, androgen receptor positive, estrogen receptor positive breast cancer.
May 28, 2014Women with hormone receptor-positive (HR+) breast cancer should be given the option to have adjuvant hormonal therapy for as long as 10 years, according to new guidelines issued today by the American Society of Clinical Oncology (ASCO).
May 27, 2014Dr. Harold Burstein, co-chair of ASCO's Expert Panel that wrote the guideline update, says that new evidence has increased the previous five-year standard.
May 25, 2014Dr. Ann Partridge, head of the Program for Young Women with Breast Cancer and wife of the New Bedford mayor, shares her passion for her family, medicine, and running.
May 22, 2014Dr. Ann Partridge provides insight into misunderstandings about breast cancer that are leading women to undergo double mastectomies.
May 2014Investigators are working to better match therapies to the size and aggressiveness of HER2-positive breast tumors. They're studying treatments that attack such tumors with a two-in-one compound of antibody and chemotherapy. And they're probing HER3, a cousin of HER2 that holds promise as a target for ovarian cancer drugs. Together, this work is making the treatment of HER2-positive breast cancers — and potentially some ovarian cancers – not only more effective but also longer-lasting and less prone to side effects.
May 2014With some women choosing a radical approach to breast cancer surgery and others opting for conservative techniques, surgeons at the Susan F. Smith Center for Women's Cancers at Dana-Farber tailor the latest methods to the medical and personal needs of each patient.
May 2014Over the past 15 years, smart drugs have gained a permanent place in the anti-cancer arsenal, as scientists have identified dozens of potential target genes and proteins and developed an expanding array of drugs capable of hitting those targets. Today, researchers and physicians at the Susan F. Smith Center for Women's Cancers at Dana-Farber are pioneering work in laboratory discoveries, drug development, and clinical applications that have led to the advent of targeted therapies for breast and gynecologic cancers.
April 6, 2014Dr. Eric Winer provides insight into a new type of drug that can help prevent advanced breast cancer from progressing.
April 6, 2014Dr. Judy Garber and Dr. Eric Winer provided expert comment on an experimental medicine that has slowed the pace of advanced breast cancer, doubling the amount of time that patients could live without their tumors advancing.
April 4, 2014Dr. Rachel Freedman comments on a recent study about the racial gap in breast cancer care.
April 3, 2014A young woman in her prime, with a full life and meaningful career, does not expect a cancer diagnosis. But that is what happened to 34-year-old Erin, who received the news when she was in Paris with her mother and sister, on a long-awaited trip to celebrate Mother's Day.
December 2, 2013When I was diagnosed with breast cancer at age 28, during my last semester of graduate school, I remember thinking that this had to mean something. I needed to turn an unfortunate situation into something positive, so I decided to pursue oncology nursing where I felt I could make a difference.
October 30, 2013 Increasing evidence through research at Dana-Farber and elsewhere supports the use of acupuncture as a remedy for some of the symptoms breast cancer patients experience. This integrative therapy can be used in conjunction with radiation and chemotherapy.
September 18, 2013 Young women with breast cancer often respond with a "yes" and overestimate the need to have the healthy breast surgically removed, according to a recent study by Dana-Farber investigators. However, the actual risk of cancer occurring in the healthy breast of those women without a genetic predisposition to breast cancer is only two to four percent.
All breast cancer news releases >>
All breast cancer media coverage >>
All breast cancer blog posts >>
Support Research and Treatment at the Susan F. Smith Center
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: